Abstract
To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55% of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1%. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1% of the patients, and 43.6% had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.
| Original language | English |
|---|---|
| Pages (from-to) | 35-40 |
| Number of pages | 6 |
| Journal | Brain and Development |
| Volume | 22 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2000 |
Fingerprint
Keywords
- Epilepsy
- Infant
- Newborn
- Phenytoin
- Status epilepticus
ASJC Scopus subject areas
- Clinical Neurology
- Pediatrics, Perinatology, and Child Health
- Neurology
Cite this
Phenytoin administration in the newborn and infant. / Sicca, Federico; Contaldo, Annarita; Rey, Elisabeth; Dulac, Olivier.
In: Brain and Development, Vol. 22, No. 1, 01.01.2000, p. 35-40.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phenytoin administration in the newborn and infant
AU - Sicca, Federico
AU - Contaldo, Annarita
AU - Rey, Elisabeth
AU - Dulac, Olivier
PY - 2000/1/1
Y1 - 2000/1/1
N2 - To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55% of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1%. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1% of the patients, and 43.6% had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.
AB - To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55% of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1%. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1% of the patients, and 43.6% had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.
KW - Epilepsy
KW - Infant
KW - Newborn
KW - Phenytoin
KW - Status epilepticus
UR - http://www.scopus.com/inward/record.url?scp=0033969340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033969340&partnerID=8YFLogxK
U2 - 10.1016/S0387-7604(99)00110-2
DO - 10.1016/S0387-7604(99)00110-2
M3 - Article
C2 - 10761832
AN - SCOPUS:0033969340
VL - 22
SP - 35
EP - 40
JO - Brain and Development
JF - Brain and Development
SN - 0387-7604
IS - 1
ER -